Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The GUARD Trial - Part 1: A Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 Versus Standard-of-Care for Prevention of Proliferative Vitreoretinopathy

NCT04136366 is registered in ClinicalTrials.gov with Aldeyra Therapeutics, Inc. as lead sponsor.

NCT NCT04136366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04136366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The GUARD Trial - Part 1: A Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 Versus Standard-of-Care for Prevention of Proliferative Vitreoretinopathy
Lead sponsor
Aldeyra Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 15, 2019
Completion date
June 14, 2022
Enrollment
106 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

proliferative vitreoretinopathy